Manfred Wirth: h-index, Total Citations, and Citation Map
Manfred Wirth's h-index is 76 (394 i10-index, 28,853+ total citations across 1,000+ publications) according to Google Scholar as of July 2026. Manfred Wirth is affiliated with Technische Universität Dresden.
Manfred Wirth is a researcher affiliated with Technische Universität Dresden, specializing in Urologie. Their work has been cited 28,853 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Manfred Wirth's Citation Metrics
Bibliometric impact based on 1,000 indexed publications.
- H-Index
- 76
- i10-Index
- 394
- Total Citations
- 28,853
- Citing Countries
- 3
As of July 2026.
Manfred Wirth has an h-index of 76 and 28,853 total citations across 1000 publications, with research cited by institutions in 3 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Manfred Wirth's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Enzalutamide in metastatic prostate cancer before chemotherapy
20143,907
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Manfred Wirth's research
Manfred Wirth is a researcher in Urologie at Technische Universität Dresden. Their work has been cited 28,853 times across 1,000 publications (h-index 76), according to Google Scholar.
Their most-cited work, “Enzalutamide in metastatic prostate cancer before chemotherapy” (2014), has accumulated 3,907 citations. Other influential works include “Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable …” (2009) with 1,026 citations and “Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial” (2021) with 705 citations.
Citations of Manfred Wirth's research come primarily from China, United Kingdom and United States, reflecting international research impact. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
